The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

Congress needs to act to bring needed reforms into the 340B to make revenue from the drug pricing program more transparent and to ensure patients are benefiting from the discounts, according to a ...

The Trump administration has approved eight drugmakers' rebate plans for a controversial 340B drug discount pilot program that kicks off Jan. 1. The 340B Rebate Model Pilot Program, unveiled this ...

Created in 1992, the 340B Drug Pricing Program is a U.S. federal government program intended to give safety net providers—those that organize and deliver a significant level of both healthcare and ...

We are pleased to resume publication of the Latham & Watkins Drug Pricing Digest, which covers all things market access — including recent developments in the Medicaid Drug Rebate Program, Medicare ...

The 340B drug discount program would work better if the money followed the patient rather than going directly to hospitals, Anthony DiGiorgio, DO, MHA, said Monday at an event on 340B sponsored by the ...

In U.S. healthcare, few policies are as poorly designed as the 340B drug discount program. But despite solid evidence that the program is poorly managed, the government has once again denied being ...